Aurora Spine Corp. · TSXV:ASG
Aurora Spine — Lytham Partners Spring 2026 Investor Conference
17 slides from Aurora Spine's conference presentation, May 2026
Slide 1: Lytham Partners Spring 2026 Investor Conference May 28th
SIMPLIFING THE COMPLEX Lytham Partners Spring 2026 TSXV: ASG Investor Conference May 28th OTCQB: ASAPF
Slide 2: Forward Looking Disclaimer
Forward Looking Disclaimer This presentation contains certain statements that may be deemed "forward-looking statements." All statements in this document, other than statements of historical fact, that address events or developments that the Company expects to occur, are forward looking statements.
Slide 3: Key Value Creation Driver: Proprietary Products
KEY VALUE CREATION DRIVER: Proprietary Products Aurora Spine, Inc.
Slide 4: Proprietary Product Platforms
Proprietary Product Platforms Aurora Spine currently has several Hydra proprietary product platforms, created to add significant value to the company. Launched 2024 Patented Technology FDA 510K Cleared. Scoli/Deformity DEXA-C Launched 2023 Patented Technology FDA 510K Cleared. Cervical & Lumbar DEXA
Slide 5: Proprietary Product: zip Series
Proprietary Product: zip Series The zip is Aurora Spine’s minimally invasive interspinous fixation implant for spinal fusion (screwless procedure). It was developed as an alternative to pedicle screw fixation. • Over 10,000 procedures performed to date • Reduces OR time by 36%: 98 minutes vs. 153 mi
Slide 6: Proprietary Product: SiLO TFX
Proprietary Product: SiLO TFX SiLO TFX is Aurora Spine's MIS Transfixing Si Joint Fusion System. • A Crossover product: Ortho, Neuro, and Pain Physicians can all use this product. • Commercially Launched: Q2:23 • Fastest growing product for Aurora SiLO Revenues by Year $10 $8.2 $7.7 $8 $USD in Milli
Slide 7: Proprietary Product: DEXA Technology & apollo
Proprietary Product: DEXA Technology & apollo • The apollo is part of the DEXA Technology family of products. • The system is comprised of cervical plates and bone screws constructed of titanium alloy. • A wide array of implant length options to match a variety of patient anatomies and to facilitate
Slide 8: Proprietary Product: DEXA-C
Proprietary Product: DEXA-C Having low bone density or osteoporosis affects 54 million Americans. The DEXA-C Cervical Interbody Cage can match the bone density of the patient, promote bone growth, and provide better implantation. • Implant stiffness correlates to Bone Quality • Acts and looks like b
Slide 9: Proprietary Product: DEXA-L
Proprietary Product: DEXA-L A Lumbar Interbody Fusion System The DEXA-L Stand-Alone ALIF System can match the bone density of the patient, promote bone growth, and provide better implantation. • Implant stiffness correlates to Bone Quality • Acts and looks like bone • DEXA-L tunes its stiffness to m
Slide 10: New Product Offerings: Aurora Branded Line of Biologics
New Product Offerings: Aurora Branded Line of Biologics • Launched Q4:25 • Every procedure using an Aurora product requires biologics • New biologics to increase offerings • Offering a complete suite of allograft solutions: and lead to margin improvement • TURBO FUSE Fiber Putty • OSTEO GRAFT DBM Pu
Slide 11: Aurora MIS Portfolio: Continuum of Care
Aurora MIS Portfolio: Continuum of Care Treatment of Degenerative Cascade aurora-spine.com Confidential
Slide 12: Strong Patent Portfolio
Strong Patent Portfolio Title Ser. or Pat. No Filing Date Issue Date Continuity Data Status Dynamic and Non-Dynamic Interspinous Fusion Implant and Granted 9,364,267 4-17-13 6-14-16 Bone Growth Stimulation 7.5 Year MF Open 6-14-23 System Aurora Spine’s Intellectual Dynamic and Non-Dynamic Granted In
Slide 13: Financials
FINANCIALS Aurora Spine, Inc.
Slide 14: Income Statement Highlights - Quarterly
Income Statement Highlights - Quarterly Revenue Gross Profit Margins Adjusted EBITDAC $6 65% $1 62.4% $0.4 $5.0 61.9% 62.2% 62.4% $0 $5 60.5% 60.9% $0.3 $4.8$4.7 59.7% $0 60% 58.0% $4.4$4.5$4.4 57.8% $0 $0.1$0.2 $5 56.9% 56.7% $4.1 $0.1$0.1$0.1$0.1 $3.9$3.9$4.0 $USD in Millions $0 $4 55% $ in USD $3
Slide 15: Balance Sheet Highlights
Balance Sheet Highlights $ in USD 12/31/2025 9/30/2025 12/31/2024 Cash and cash equivalents $896,713 $665,757 $825,621 Accounts receivable, net $3,310,537 $4,208,468 $3,784,858 Inventory $3,243,257 $3,818,985 $3,613,557 Total current assets $7,801,004 $8,874,876 $8,500,120 Property, plant and equipm
Slide 16: Capitalization Summary
Capitalization Summary Stock Details Key Shareholders Stock price: $0.20 25.2% - All Insiders (Board of Directors and 52-week range: $0.17-$0.29 Management) Shares outstanding: 78.1 million 16.1% - David Rosenkrantz, Chairman Market capitalization: $15.6 million 6.9% - Trent Northcutt, CEO 2.2% - Ot
Slide 17: Milestones And Objectives
Milestones And Objectives Proprietary product platforms to drive revenue growth and profitability • ZIPTM Interspinous Fixation Device – screwless procedure • SiLO-TFXTM – novel solution for SI Joint pain; growing rapidly in expanding market • DEXATM products: DEXA-C and the launch of DEXA-L for lum
Aurora Spine — Lytham Partners Spring 2026 Investor Conference on 6ix